Compare Bristol-Myers Squibb Co (BMY) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs 10X Genomics Inc — how do they compare? Bristol-Myers Squibb Co trades at $58.93 (market cap $116.30B), while 10X Genomics Inc trades at $45.07 (market cap $5.81B). The key difference: Bristol-Myers Squibb Co is far larger — about 20× 10X Genomics Inc's market cap, and Bristol-Myers Squibb Co pays a 4.42% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| BMY | TXG | |
|---|---|---|
Market Cap | $116.30B | $5.81B |
Sector | Health | Health |
52-Week High | $62.37 | $45.80 |
52-Week Low | $42.60 | $11.34 |
Enterprise Value | $152.24B | $5.36B |
Dividend Yield | 4.42% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
